HSP90 as a platform for the assembly of more effective cancer chemotherapy

►Inhibitors of HSP90 have been valuable probes in learning how this chaperone supports malignancy. ►Clinical activity for first generation inhibitors has been limited against advanced cancers. ►Next generation drugs with better pharmacology are more promising, but remain far from curative. ►Combining HSP90 inhibitors with other anticancer drugs could limit the evolvability of cancers. ►Hurdles arise in executing trials that combine proprietary agents, but the rewards could be great.